Metagenomi Therapeutics (MGX) EBIT Margin (2023 - 2026)
Metagenomi Therapeutics' (MGX) quarterly EBIT Margin came in at 1970.11% in Q1 2026, down 129601.0% year-over-year from N/an in Q1 2025, and down 216.21% quarter-over-quarter from 623.04% in Q4 2025.
Powered by 
Analysis
Metagenomi Therapeutics (MGX) EBIT Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported EBIT Margin for 4 consecutive years, with 1970.11% the latest figure, recorded in Q1 2026.
- On a quarterly basis, EBIT Margin fell 129601.0% year-over-year to 1970.11% in Q1 2026; TTM through Mar 2026 was 415.48%, a 22174.0% decrease from a year earlier, with the FY2025 full-year figure at 380.85%, down 21085.0% from the prior year.
- EBIT Margin was 1970.11% for Q1 2026 at Metagenomi Therapeutics, down from 623.04% in the prior quarter.
- Over five years, EBIT Margin peaked at 84.28% in Q2 2024 and troughed at 1970.11% in Q1 2026.
- A 4-year average of 403.12% and a median of 214.51% in 2024 frame the typical range for EBIT Margin.
- Across the five-year window, EBIT Margin soared 7416 bps in 2024 and slumped 129601 bps in 2026, its largest moves.
- Over 4 years, EBIT Margin stood at 162.88% in 2023, then plunged by 32 bps to 214.51% in 2024, then sank by 190 bps to 623.04% in 2025, then plunged by 216 bps to 1970.11% in 2026.
- The last three EBIT Margin figures came in at 1970.11% (Q1 2026), 623.04% (Q4 2025), and 263.76% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | -25,827.14% |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 0.56% |
| 10 | Metagenomi Therapeutics | 44.20 Mn | 44.20 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1,970.11% |
| Dec 31, 2025 | -623.04% |
| Sep 30, 2025 | -263.76% |
| Jun 30, 2025 | -246.53% |
| Mar 31, 2025 | -674.10% |
| Dec 31, 2024 | -214.51% |
| Sep 30, 2024 | -194.40% |
| Jun 30, 2024 | -84.28% |
| Mar 31, 2024 | -260.17% |
| Dec 31, 2023 | -162.88% |
| Sep 30, 2023 | -181.15% |
| Jun 30, 2023 | -158.45% |
| Mar 31, 2023 | -207.21% |